Immune modulation with a staphylococcal preparation in fibromyalgia/ chronic fatigue syndrome: Relation between antibody levels and clinical improvement

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 23, Issue 2, 2004, Pages 98-105

  Zachrisson, O ^a   Colque Navarro, P ^b   Gottfries, C G ^a   Regland, B ^a   Mollby R ^b  

^a Institute of Neuroscience and Physiology   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOXIN; BACTERIAL ANTIGEN; ENTEROTOXIN; ENZYME; IMMUNOGLOBULIN G; PLACEBO; STAPHYLOCOCCUS TOXOID; STAPHYLOCOCCUS VACCINE; STAPHYPAN BERNA; TRIACYLGLYCEROL LIPASE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFECT; EVALUATION; FEMALE; FIBROMYALGIA; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL PARAMETERS; IMMUNOMODULATION; IMMUNOSTIMULATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SEROLOGY; STAPHYLOCOCCUS; SYMPTOM; VACCINATION;

ADULT; ANTIBODIES, BACTERIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATIGUE SYNDROME, CHRONIC; FEMALE; FIBROMYALGIA; FOLLOW-UP STUDIES; HUMANS; IMMUNITY; MALE; MIDDLE AGED; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; SEROLOGIC TESTS; STAPHYLOCOCCAL VACCINES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 1642330292     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-003-1062-8     Document Type: Article

References (52)

1. Buchwald D, Garrity D (1994) Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. Arch Intern Med 154:2049-2053
2. Buchwald D (1996) Fibromyalgia and chronic fatigue syndrome: similarities and differences. Rheum Dis Clin North Am 22:219-243
3. White KP, Speechley M, Harth M, Ostbye T (2000) Co-existence of chronic fatigue syndrome with fibromyalgia syndrome in the general population. A controlled study. Scand J Rheumatol 29:44-51
4. Aaron LA, Burke MM, Buchwald D (2000) Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med 160:221-227
5. Aaron LA, Herrell R, Ashton S, Belcourt M, Schmaling K, Goldberg J, Buchwald D (2001) Comorbid clinical conditions in chronic fatigue: a co-twin control study. J Gen Intern Med 16:24-31
6. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al. (1990) American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33:160-172
7. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A (1994) The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121:953-959
8. Buskila D, Press J, Gedalia A, Klein M, Neumann L, Boehm R, Sukenik S (1993) Assessment of nonarticular tenderness and prevalence of fibromyalgia in children. J Rheumatol 20:368-370
9. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L (1995) The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38:19-28
10. White KP, Speechley M, Harth M, Ostbye T (1999) The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 26:1570-1576
11. Wessely S, Chalder T, Hirsch S, Wallace P, Wright D (1997) The prevalence and morbidity of chronic fatigue and chronic fatigue syndrome: a prospective primary care study. Am J Public Health 87:1449-1455
12. Kawakami N, Iwata N, Fujihara S, Kitamura T (1998) Prevalence of chronic fatigue syndrome in a community population in Japan. Tohoku J Exp Med 186:33-41
13. Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, Taylor RR, McCready W, Huang CF, Plioplys S (1999) A community-based study of chronic fatigue syndrome. Arch Intern Med 159:2129-2137
14. Goldenberg DL (1993) Do infections trigger fibromyalgia? Arthritis Rheum 36:1489-1492
15. Goldenberg DL (1999) Fibromyalgia syndrome a decade later: what have we learned? Arch Intern Med 159:777-785
16. Butt HL, Dunstan RH, McGregor NR, Roberts TK, Zerbes M, Klineberg IJ (1998) An association of membrane-damaging toxins from coagulase-negative staphylococci and chronic orofacial muscle pain. J Med Microbiol 47:577-584
17. White PD, Thomas JM, Amess J, Crawford DH, Grover SA, Kangro HO, Clare AW (1998) Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. Br J Psychiatry 173:475-481
18. Patarca-Montero R, Antoni M, Fletcher MA, Klimas NG (2001) Cytokine and other immunologic markers in chronic fatigue syndrome and their relation to neuropsychological factors. Appl Neuropsychol 8:51-64
19. van West D, Maes M (2001) Neuroendocrine and immune aspects of fibromyalgia. BioDrugs 15:521-531
20. Fleming A (1939) Recent advances in vaccine therapy. Br Med J 15:100-104
21. Dolman CE, Lond MRCP (1935) Clinical uses of staphylococcus toxoid. Lancet, Feb 9:306-313
22. Andersson M, Bagby JR, Dyrehag LE, Gottfries CG (1998) Effects of staphylococcus toxoid vaccine on pain and fatigue in patients with fibromyalgia/chronic fatigue syndrome. Eur J Pain 2:133-142
23. Åsberg M, Montgomery SA, Perris C, Schalling D, Sedvall G (1978) A comprehensive psychopathological rating scale. Acta Psychiatr Scand 271 (Suppl):5-27
24. Zachrisson O, Regland B, Jahreskog M, Jonsson M, Kron M, Gottfries CG (2002) Treatment with staphylococcus toxoid in fibromyalgia/chronic fatigue syndrome - a randomized controlled trial. Eur J Pain 6:455-466
25. Burckhardt CS, Clark SR, Bennett RM (1991) The fibromyalgia impact questionnaire: development and validation. J Rheumatol 18:728-733
26. Perris C (1979) Reliability and validity studies of the Comprehensive Psychopathological Rating Scale (CPRS). Prog Neuropsychopharmacol 3:413-421
27. Kanclerski K, Soderquist B, Kjellgren M, Holmberg H, Möllby R (1996) Serum antibody response to Staphylococcus aureus enterotoxins and TSST-1 in patients with septicaemia. J Med Microbiol 44:171-177
28. Möllby R (1983) Isolation and properties of membrane-damaging toxins. In: Easmon CSF, Adlam C (eds) Staphylococci and staphylococcal disease. Academic Press, London, ??
29. Reizenstein E, Hallander HO, Blackwelder WC, Kuhn I, Ljungman M, Möllby R (1995) Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. J Immunol Methods 183:279-290
30. Colque-Navarro P, Soderquist B, Holmberg H, Blomqvist L, Olcen P, Möllby R (1998) Antibody response in Staphylococcus aureus septicaemia - a prospective study. J Med Microbiol 47:217-225
31. Kanclerski K, Möllby R (1987) A simple and exact two-point interpolation method for determination of haemolytic activity in microtiter plates. Acta Pathol Microbiol Immunol Scand [B] 95:175-179
32. Julander IG, Granstrom M, Hedstrom SA, Möllby R (1983) The role of antibodies against alpha-toxin and teichoic acid in the diagnosis of staphylococcal infections. Infection 11:77-83
33. Tyski S, Colque-Navarro P, Hryniewicz W, Granstrom M, Möllby R (1991) Lipase versus teichoic acid and alpha-toxin as antigen in an enzyme immunoassay for serological diagnosis of Staphylococcus aureus infections. Eur J Clin Microbiol Infect Dis 10:447-449
34. Möllby R (1991) The antibody response in staphylococcal infections: diagnostic and therapeutic applications. The staphylococci. Zentralbl Bakteriol (Suppl) 21:61-68
35. Lee JC (2001) Development of antistaphylococcal vaccines. Curr Infect Dis Rep 3:517-524
36. Söderquist B, Colque-Navarro P, Blomqvist L, Olcén P, Holmberg H, Möllby R (1993) Enzyme immunoassay for detection of alpha-toxin from Staphylococcus aureus. Serodiagn Immunother Infect Dis 5:23-26
37. Mudd S (1971) Resistance against Staphylococcus aureus. JAMA 218:1671-1673
38. Proctor RA, Kahl B, von Eiff C, Vaudaux PE, Lew DP, Peters G (1998) Staphylococcal small-colony variants have novel mechanisms for antibiotic resistance. Clin Infect Dis 27 (Suppl 1):68-74
39. von Eiff C, Proctor RA, Peters G (2000) Staphylococcus aureus small-colony variants: formation and clinical impact. Int J Clin Pract 115 (Suppl):44-49
40. Tarello W (2001) Chronic fatigue syndrome (CFS) associated with Staphylococcus spp. bacteremia, responsive to potassium arsenite 0.5% in a veterinary surgeon and his coworking wife, handling with CFS animal cases. Comp Immunol Microbiol Infect Dis 24:233-246
41. Hume EB, Dajcs JJ, Moreau JM, O'Callaghan RJ (2000) Immunization with alpha-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis. Infect Immun 68:6052-6055
42. Dean JH, Silva JS, McCoy JL, Chan SP, Baker JJ, Leonard C, Herberman RB (1975) In vitro human reactivity to staphylococcal phage lysate. J Immunol 115:1060-1064
43. Krishan G, et al (1994) Cytokines produced by Staphage Lysate. In: Program and abstracts of the 12th European Immunology Meeting, Barcelona, Spain, Abstract no. A123/ C/00115
44. Shayegani M, Parsons LM, Maupin PS (1980) Correlation of staphylococci-induced delayed-type hypersensitivity and non-specific resistance during their development, long-term duration and adoptive transfer. J Reticuloendothel Soc 28:265-274
45. Nilsson IM, Verdrengh M, Ulrich RG, Bavari S, Tarkowski A (1999) Protection against Staphylococcus aureus sepsis by vaccination with recombinant staphylococcal enterotoxin A devoid of superantigenicity. J Infect Dis 180:1370-1373
46. Christensson B, Hedstrom SA (1985) Serological response to toxic shock syndrome toxin in Staphylococcus aureus infected patients and healthy controls. Acta Pathol Microbiol Immunol Scand [B] 93:87-90
47. Nordin U, Wannfors K, Colque-Navarro P, Mollby R, Heimdahl A (1995) Antibody response in patients with osteomyelitis of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 79:429-435
48. Gupta S, Vayuvegula B (1991) A comprehensive immunological analysis in chronic fatigue syndrome. Scand J Immunol 33:319-327
49. Regland B, Zachrisson O, Stejskal V, Gottfries CG (2001) Nickel allergy is found in a majority of women with chronic fatigue syndrome and muscle pain - and may be triggered by cigarette smoke and dietary nickel intake. J Chronic Fatigue Syndr 8:57-65
50. Borg L, Christensen JM, Kristiansen J, Nielsen NH, Menne T, Poulsen LK (2000) Nickel-induced cytokine production from mononuclear cells in nickel-sensitive individuals and controls. Cytokine profiles in nickel-sensitive individuals with nickel allergy-related hand eczema before and after nickel challenge. Arch Dermatol Res 292:285-291
51. Straus SE, Dale JK, Wright R, Metcalfe DD (1988) Allergy and the chronic fatigue syndrome. J Allergy Clin Immunol 81:791-795
52. Benson M, Strannegard IL, Wennergren G, Strannegard O (2000) Low levels of interferon-gamma in nasal fluid accompany raised levels of T-helper 2 cytokines in children with ongoing allergic rhinitis. Pediatr Allergy Immunol 11:20-28